Ind Swift Laboratories Reports Strong Profit Growth and Completes Merger with Ind Swift Limited Aug 11, 2025
Ind-Swift Laboratories Merger with Ind-Swift Limited Gets NCLT Approval, Effective August 8, 2025 Jul 31, 2025
More news about Ind Swift Laboratories
28Jul 25
Ind-Swift Laboratories Secures NCLT Approval for Merger with Ind-Swift Limited
Ind Swift Laboratories Limited (ISLL) has obtained final approval from the National Company Law Tribunal (NCLT) for its merger with Ind-Swift Limited. The NCLT Chandigarh Bench approved the amalgamation scheme, which will affect shareholders and creditors of both companies. ISLL has made the NCLT order publicly available on its website for transparency. The merger is expected to streamline operations and create potential synergies between the two entities.
18Jun 25
Ind-Swift Laboratories Invests ₹950 Million in Khandelwal Finance's OCRPS
Ind-Swift Laboratories has approved an investment of ₹950.00 million in Khandelwal Finance through Optionally Convertible Redeemable Preference Shares (OCRPS). This strategic move represents a significant financial decision for the pharmaceutical company, potentially diversifying its investment portfolio and providing opportunities for future equity conversion or steady income through fixed dividends.
Ind-Swift Laboratories Ltd (ISLL) has approved a short-term advance of up to Rs 20 crore to Ashok Investors Trust Limited (AITL), a registered NBFC. The advance is in the form of an Inter-Corporate Deposit with a 30-day term, extendable for another 30 days, at 10% annual interest. The transaction is secured by post-dated cheques and is not a related party transaction. ISLL already holds 800 NCDs of AITL, each with a face value of Rs 5,00,000.